USPs - The Rationale

The pharmaceutical industry has reached the point where the discovery of new molecular entities has become very difficult and expensive.

Recognising and exploiting the maximal value, which can be generated by existing compounds, now constitutes an important driver of revenue growth.

At the same time, it is a well-known fact that the right drug delivery system is critical to the success of a pharmaceutical product. Introducing MediChew® tablets of existing pharmaceutical products create additional tangible patient benefits that cannot be attained through any other drug delivery system. These new benefits lead to new competitive advantages and subsequently to increased revenue and profitability.